Pediatric GLP-1 Prescribing: The Clinical Criteria and Ethical Considerations

The FDA's approval of semaglutide for adolescents aged 12 and older with obesity in late 2023 — followed by tirzepatide's expanded indication — opened a new frontier in pediatric weight management. For parents, pediatricians, and adolescents navigating this decision, the clinical and ethical landscape is complex. Here's what the evidence supports and what thoughtful prescribing looks like.

FDA-Approved Indications for Adolescents

As of 2026, semaglutide (Wegovy) is FDA-approved for weight management in adolescents aged 12 years and older with a BMI at or above the 95th percentile for age and sex (the clinical definition of obesity in pediatric populations). The approval was based on the STEP TEENS trial, which demonstrated an average body weight reduction of approximately 16% with semaglutide 2.4 mg versus 0.6% with placebo over 68 weeks.

Tirzepatide has received expanded approval for similar indications, supported by the SURMOUNT-2 adolescent data showing even greater weight reduction in the 12-17 age group.

It's worth noting that these medications are approved for adolescents with obesity, not for adolescents who are merely overweight. The clinical threshold is specific, and appropriate prescribing begins with accurate BMI-for-age percentile assessment using CDC growth charts.

When Medication Is Clinically Appropriate

The decision to prescribe GLP-1 medication to an adolescent should never be the first intervention. Clinical guidelines from the American Academy of Pediatrics (AAP) recommend a staged approach:

1. Stage 1: Health behavior and lifestyle treatment — dietary counseling, increased physical activity, family-based behavioral support. Minimum 3-6 months before advancing.
2. Stage 2: Intensive health behavior and lifestyle treatment (IHBLT) — structured programs with 26+ hours of face-to-face contact over 3-12 months, including family involvement.
3. Stage 3: Pharmacotherapy — GLP-1 medications are appropriate when stages 1-2 have been attempted and the adolescent continues to have severe obesity with or without comorbidities.
4. Stage 4: Metabolic and bariatric surgery — reserved for severe obesity with serious comorbidities when other interventions have been insufficient.

In practice, the "failed lifestyle modification" requirement should be interpreted compassionately. Many adolescents with severe obesity face biological, social, and environmental factors that lifestyle modification alone cannot overcome. Requiring prolonged struggle before offering pharmacological help can be harmful in itself.

Ethical Considerations in Adolescent Prescribing

Prescribing GLP-1 medications to minors raises ethical questions that don't apply to adult treatment:

Informed assent and consent: Adolescents should participate meaningfully in the decision-making process (assent), while parents or guardians provide legal consent. The adolescent's understanding of the medication, its effects, side effects, and the expectation of long-term treatment should be assessed and documented.

Body image and development: Adolescence is already a period of intense body image awareness and identity formation. Introducing a weight loss medication requires sensitivity to how this intervention may affect the adolescent's relationship with their body, food, and self-image. Mental health screening and ongoing psychological support are particularly important in this population.

Long-term commitment: GLP-1 medications for obesity are generally understood as long-term treatments. Prescribing a medication to a 13-year-old with the expectation that they may need to take it for decades raises questions about lifetime medication burden, unknown long-term effects in developing bodies, and the evolving capacity of the adolescent to manage their own healthcare as they transition to adulthood.

Social context: Weight stigma in schools and peer groups is already intense. Being on a weight loss medication may subject the adolescent to additional social attention — both positive and negative. Providers should discuss privacy and disclosure with both the adolescent and family.

Monitoring Differences in Adolescent Patients

Clinical monitoring for adolescents on GLP-1 medications includes all adult monitoring parameters plus several age-specific considerations:

• Growth monitoring: Height velocity should be tracked to ensure the medication isn't affecting normal pubertal growth.
• Pubertal development: Tanner staging assessment at baseline and periodically to monitor for any effects on pubertal timing.
• Bone density: Rapid weight loss during adolescence — a critical period for bone mineral density accrual — warrants vigilance. Adequate calcium, vitamin D, and weight-bearing exercise are essential.
• Mental health: More frequent screening than in adults — at baseline, 3 months, 6 months, and annually, using age-appropriate validated instruments.
• Nutritional adequacy: Adolescents have higher nutritional demands for growth and development. Dietitian involvement is strongly recommended to ensure adequate protein, calcium, iron, and micronutrient intake despite reduced appetite.